Carina Ämmälä,
Team leader, Cardiovascular, Renal and Metabolism
Dr Carina Ämmälä is team leader for in vitro islet biology in the Cardiovascular Renal and Metabolism department at AstraZenca. She joined in 2010 and has since led the development of innovative novel models to investigate the function human insulin secreting islets of Langerhans. Most recently Dr Ämmälä and colleagues have developed a model of organ-cross talk using human islet and hepatocyte organoids, a microphysiological system that is now being applied in diabetes drug discovery for mechanistic studies exploring novel targets. Prior to joining AstraZeneca, Dr Ämmälä worked for 10 years at GlaxoSmithKline in preclinical drug discovery with a focus on progressing targets improving functional islet mass as treatments for type 2 diabetes. Dr Ämmälä holds a PhD in Physiology from University of Gothenburg and an MSc in engineering physics for Chalmers University of Technology.
|
|
|
